The US Oncology Network Vision of The Network Advancing Cancer Care Realigning Reimbursement Commitment to Research Healthcare Technology Physician Governance Joining The Network US Oncology Research Physician Leadership US Oncology Research Trials Proven Support Technology Integration Resources Videos LegisLink Event Calendar Find a Physician or Practice | Find a Clinical Trial

Home > Oncologist Home > US Oncology Research > US Oncology Research Trials US Oncology Research Trials US Oncology Research provides novel therapies to patients in the community setting and allows participatation in landmark clinical trials. Use the search function below to view all open trials currently being conducted by US Oncology Research. View All... Bladder Cancer Brain Cancer Breast Cancer Colon Cancer Gastric Cancer Head and Neck Cancer Hematologic ITP Leukemia Liver Cancer Lung Cancer Lymphomas Myelodysplastic Syndrome Myelomas Neuroendocrine Tumors Ovarian Cancer Pancreatic Cancer Prostate Cancer Rectal Cancer Renal Cancer Sarcoma Skin Cancer Solid Tumors Supportive Care CLINICAL TRIAL SEARCH RESULTS Trial Number: NCT01126749 Cancer Type: Bladder Cancer An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer (E7389-702) Read More Trial Number: NCT01282463 Cancer Type: Bladder Cancer An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy (IMCL CP20-0902) Read More Trial Number: NCT01062399 Cancer Type: Brain Cancer Phase I/II trial of concurrent RAD001 (Everolimus) with Temozolomide/Radiation followed by adjuvant RAD001/Temozolomide in newly diagnosed glioblastoma (RTOG 0913) Read More Trial Number: NCT01576666 Cancer Type: Brain Cancer (CLDE225X2114) A Phase 1b, multi-center, open label, dose escalation study of oral LDE225 in combination with BKM120 in patients with advanced solid tumors Read More Trial Number: NCT01609790 Cancer Type: Brain Cancer RTOG 1122: Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma Read More Trial Number: NCT01421524 Cancer Type: Brain Cancer A Phase 1A/1B, Multi-Center, Open-Label, Dosing finding study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the pleiotropic pathway modifier CC-122 administered orally to subjects with advanced solid tumors, non-Hodgkin’s lymphoma or multiple myeloma (CC-122-ST-001) Read More Trial Number: NCT00968968 Cancer Type: Breast Cancer A Randomized, Phase III, Open-label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer (LPT112515) Read More Trial Number: NCT00769379 Cancer Type: Breast Cancer A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation and Radiation Alone for Women with Her2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Read More Trial Number: NCT01421472 Cancer Type: Breast Cancer MM-121-02-02-07:A Randomized, Phase 2 Trial of Preoperative MM-121 with Paclitaxel in HER2-negative Breast Cancer Read More Trial Number: NCT01572727 Cancer Type: Breast Cancer CBKM120F2202: A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pathway activation Read More Trial Number: NCT01492101 Cancer Type: Breast Cancer 11-PIR-11: The BEACON Study (Breast Cancer Outcomes With Nktr-102): A Phase 3 Open-Label, Randomized, Multicenter Study Of NKTR-102 Versus Treatment Of Physician’s Choice (TPC) In Patients With Locally Recurrent Or Metastatic Breast Cancer Previously Treated With An Anthracycline, A Taxane, And Capecitabine Read More Trial Number: NCT01663727 Cancer Type: Breast Cancer Protocol GO25632: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Bevacizumab, And Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo As First-Line Treatment Of Patients With HER2-Negative Metastatic Breast Cancer IND#113704 Read More Trial Number: NCT01528345 Cancer Type: Breast Cancer A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ breast cancer that have evidence of disease progression on or after prior endocrine therapy (CTKI258A2210) Read More Trial Number: NCT01349322 Cancer Type: Breast Cancer A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer (RTOG 1005) Read More Trial Number: NCT01610284 Cancer Type: Breast Cancer (CBKM120F2302) A phase III randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment Read More Trial Number: NCT01358877 Cancer Type: Breast Cancer A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer (BIG4-11/BO25126/TOC4939G) BIG 4-11 / BO25126 / TOC4939G (PK substudy 1) A pharmacokinetic substudy in association with the Phase III, randomized, multicenter, double-blind, placebo-controlled trial APHINITY (BIG 4-11 / BO25126 / TOC4939g) to evaluate pharmacokinetics and potential drug-drug interactions in patients with early breast cancer Read More Trial Number: NCT01576666 Cancer Type: Breast Cancer (CLDE225X2114) A Phase 1b, multi-center, open label, dose escalation study of oral LDE225 in combination with BKM120 in patients with advanced solid tumors Read More Trial Number: NCT01547741 Cancer Type: Breast Cancer NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Read More Trial Number: NCT01633060 Cancer Type: Breast Cancer A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment (CBKM120F2303) Read More Trial Number: NCT01275677 Cancer Type: Breast Cancer A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer Read More Trial Number: NCT01740336 Cancer Type: Breast Cancer GO28509: A Phase II, Randomized Study of Paclitaxel with GDC-0941 versus Paclitaxel with Placebo in Patients with Locally Recurrent or Metastatic Breast Cancer Read More Trial Number: NCT01296555 Cancer Type: Breast Cancer Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CANCER Read More Trial Number: NCT01183780 Cancer Type: Colon Cancer Protocol I4T-MC-JVBB (also known as IMCL CP12 0920) A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine Read More Trial Number: NCT01524978 Cancer Type: Colon Cancer An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers (MO28072) Read More Trial Number: NCT01576666 Cancer Type: Colon Cancer (CLDE225X2114) A Phase 1b, multi-center, open label, dose escalation study of oral LDE225 in combination with BKM120 in patients with advanced solid tumors Read More Trial Number: NCT01309126 Cancer Type: Colon Cancer BT-CL-PGG-CRC1031: Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer Read More Trial Number: NCT01697072 Cancer Type: Gastric Cancer 20070622: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Read More Trial Number: NCT01590719 Cancer Type: Gastric Cancer A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients With Metastatic HER2-Negative Gastroesophageal Cancer (YO28252) Read More Trial Number: NCT01774851 Cancer Type: Gastric Cancer (MM-111-13-02-04) Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with 'Traditional' and 'Non-Traditional' HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy Read More Trial Number: NCT00956007 Cancer Type: Head and Neck Cancer A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER (RTOG 0920) Read More Trial Number: NCT01351935 Cancer Type: Hematologic Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia (AVL-292-003) Read More Trial Number: NCT01414855 Cancer Type: Hematologic Protocol GAO4915g: A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy. A Substudy in Association With Study GAO4915g to Evaluate CHOP Pharmacokinetics and Potential Drug-Drug Interactions When Given with GA101 Read More Trial Number: NCT01088048 Cancer Type: Hematologic (CAL 101-07) A Phase I Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Read More Trial Number: NCT01204164 Cancer Type: Hematologic TG02-101: A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies Read More Trial Number: NCT01736683 Cancer Type: Hematologic ACE-011-MDS-001: An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients with Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Read More Trial Number: NCT00547066 Cancer Type: ITP IM-T-hA20-07: A Phase I/II Study of Immunotherapy with Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients with Chronic Immune Thrombocytopenia Purpura Read More Trial Number: NCT01461538 Cancer Type: Leukemia SGN35-013: A Phase 2, open-label, study of brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies Read More Trial Number: NCT01351935 Cancer Type: Leukemia Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia (AVL-292-003) Read More Trial Number: NCT01244750 Cancer Type: Leukemia CA180330: Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY) Read More Trial Number: NCT01088048 Cancer Type: Leukemia (CAL 101-07) A Phase I Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Read More Trial Number: NCT01539512 Cancer Type: Leukemia GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia Read More Trial Number: NCT01539291 Cancer Type: Leukemia GS-US-312-0117: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia Read More Trial Number: NCT01569295 Cancer Type: Leukemia GS-US-312-0115: A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia Read More Trial Number: NCT01650805 Cancer Type: Leukemia (AP24534-12-301) A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Read More Trial Number: NCT01757535 Cancer Type: Leukemia (CC-486-AML-001) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study To Compare Efficacy And Safety Of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care As Maintenance Therapy In Subjects With Acute Myloid Leukemia In Complete Remission Read More Trial Number: NCT01799889 Cancer Type: Leukemia A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102) Read More Trial Number: NCT01421524 Cancer Type: Liver Cancer A Phase 1A/1B, Multi-Center, Open-Label, Dosing finding study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the pleiotropic pathway modifier CC-122 administered orally to subjects with advanced solid tumors, non-Hodgkin’s lymphoma or multiple myeloma (CC-122-ST-001) Read More Trial Number: NCT00858364 Cancer Type: Lung Cancer Amgen Protocol 20070782: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy Read More Trial Number: NCT01160744 Cancer Type: Lung Cancer Protocol IMCL CP12-0917: An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients with Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC) Read More Trial Number: NCT01457417 Cancer Type: Lung Cancer DEK-DKK1-P100: A Two Part, Phase 1, Multicenter, Open-Label Study of DKN-01 given Intravenously. Part A: A Dose-Escalation study in patients with multiple myeloma or advanced solid tumors. Part B: an Expansion Cohort in patients with relapsed or refractory non-small cell lung cancer (NSCLC) Read More Trial Number: NCT01523587 Cancer Type: Lung Cancer 1200.125: LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy Read More Trial Number: NCT01055197 Cancer Type: Lung Cancer RTOG 0937 Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC) Read More Trial Number: NCT1465802 Cancer Type: Lung Cancer (A7471042) ARCHER 1042: A Phase 2 Study of Dacomitinib in Advanced Non-small Cell Lung Cancer (Post-Chemotherapy or Select First Line Patients) to Evaluate Prophylactic Intervention on Dermatologic and Gastrointestinal Adverse Events and Patient Reported Outcomes Read More Trial Number: NCT01722292 Cancer Type: Lung Cancer I4J-MC-HHBE: A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination with Carboplatin and Etoposide Followed by LY2940680 versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients with Extensive-Stage Small Cell Lung Cancer Read More Trial Number: NCT01769391 Cancer Type: Lung Cancer (I4XMCJFCL) A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Read More Trial Number: NCT01657799 Cancer Type: Lung Cancer (M10-897) A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects with Brain Metastases from Non-Small Cell Lung Cancer Read More Trial Number: NCT01577654 Cancer Type: Lung Cancer Protocol EC-FV-07: A Randomized, Open-Label Phase 2 Study Of EC145 Single-Agent And The Combination Of EC145 Plus Docetaxel Versus Docetaxel Alone In Participants With Folate-Receptor Positive [FR(++)] Second Line NSCLC Read More Trial Number: NCT00931918 Cancer Type: Lymphomas Protocol C05013 - An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Read More Trial Number: NCT01321541 Cancer Type: Lymphomas PIX306: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant Read More Trial Number: NCT01294579 Cancer Type: Lymphomas OFB114612: Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) Which Has Relapsed after Rituximab Therapy or a Rituximab Containing Therapy (OFB114612) Read More Trial Number: NCT01351935 Cancer Type: Lymphomas Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia (AVL-292-003) Read More Trial Number: NCT01414855 Cancer Type: Lymphomas Protocol GAO4915g: A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy. A Substudy in Association With Study GAO4915g to Evaluate CHOP Pharmacokinetics and Potential Drug-Drug Interactions When Given with GA101 Read More Trial Number: NCT01088048 Cancer Type: Lymphomas (CAL 101-07) A Phase I Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Read More Trial Number: NCT01421667 Cancer Type: Lymphomas SGN35-012: A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL) Read More Trial Number: NCT01716806 Cancer Type: Lymphomas SGN35-015: A phase 2 single-arm, open-label study of single-agent brentuximab vedotin for front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above Read More Trial Number: NCT01691898 Cancer Type: Lymphomas GO27834: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DCDT2980S IN COMBINATION WITH RITUXIMAB OR DCDS4501A IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON HODGKIN’S LYMPHOMA Read More Trial Number: NCT01799889 Cancer Type: Lymphomas A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102) Read More Trial Number: NCT01421524 Cancer Type: Lymphomas A Phase 1A/1B, Multi-Center, Open-Label, Dosing finding study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the pleiotropic pathway modifier CC-122 administered orally to subjects with advanced solid tumors, non-Hodgkin’s lymphoma or multiple myeloma (CC-122-ST-001) Read More Trial Number: NCT01736683 Cancer Type: Myelodysplastic Syndrome ACE-011-MDS-001: An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients with Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Read More Trial Number: NCT01081028 Cancer Type: Myelomas CONNECT (TM) MM - The Multiple Myeloma Disease Registry - Registry Protocol Read More Trial Number: NCT01461538 Cancer Type: Myelomas SGN35-013: A Phase 2, open-label, study of brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies Read More Trial Number: NCT01524978 Cancer Type: Myelomas An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers (MO28072) Read More Trial Number: NCT01454297 Cancer Type: Myelomas A prospective, longitudinal, observational study in newly diagnosed multiple myeloma (MM) patients to assess the relationship between patient outcomes, treatment regimens and molecular profiles (MMRF–11–001) Read More Trial Number: NCT01375842 Cancer Type: Myelomas Protocol PCD4989g: A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Read More Trial Number: NCT01677858 Cancer Type: Myelomas A Phase 1/2 Study of Weekly Carfilzomib in Combination with Dexamethasone for Progressive Multiple Myeloma Read More Trial Number: NCT01421524 Cancer Type: Myelomas A Phase 1A/1B, Multi-Center, Open-Label, Dosing finding study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the pleiotropic pathway modifier CC-122 administered orally to subjects with advanced solid tumors, non-Hodgkin’s lymphoma or multiple myeloma (CC-122-ST-001) Read More Trial Number: NCT01524783 Cancer Type: Neuroendocrine Tumors CRAD001T2302: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin – RADIANT-4 Read More Trial Number: NCT01170650 Cancer Type: Ovarian Cancer EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer (IND # 71,713) (PROCEED) Read More Trial Number: NCT01493505 Cancer Type: Ovarian Cancer 20101129(TRINOVA-3): A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Read More Trial Number: NCT01393990 Cancer Type: Ovarian Cancer Protocol I1D-MC-JIAE: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer Read More Trial Number: NCT01715168 Cancer Type: Ovarian Cancer (ATI0918-101)A Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI-0918 in Patients with Ovarian Cancer that has Progressed or Recurred after Platinum-based Chemotherapy Read More Trial Number: NCT01013649 Cancer Type: Pancreatic Cancer A Phase III Trial Evaluating both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848) Read More Trial Number: NCT01494506 Cancer Type: Pancreatic Cancer NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398, with or without 5-Fluorouracil and Leucovorin versus 5-Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy (MM-398-07-03-01) Read More Trial Number: NCT01505530 Cancer Type: Pancreatic Cancer Protocol I1Q-MC-JDDG: A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy Read More Trial Number: NCT01576666 Cancer Type: Pancreatic Cancer (CLDE225X2114) A Phase 1b, multi-center, open label, dose escalation study of oral LDE225 in combination with BKM120 in patients with advanced solid tumors Read More Trial Number: NCT00567580 Cancer Type: Prostate Cancer A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy (RTOG 0534) Read More Trial Number: NCT00936390 Cancer Type: Prostate Cancer A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer RTOG 0815 Read More Trial Number: NCT01322490 Cancer Type: Prostate Cancer BNIT-PRV-301: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +\- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer Read More Trial Number: NCT01306890 Cancer Type: Prostate Cancer P10-3: A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer Read More Trial Number: NCT01605227 Cancer Type: Prostate Cancer A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100 (XL184-307) Read More Trial Number: NCT01664923 Cancer Type: Prostate Cancer MDV3100-09: STRIVE: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Men with Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy Read More Trial Number: NCT01546987 Cancer Type: Prostate Cancer RTOG 1115: Phase III Trial of Dose Escalated Radiation Therapy And Standard Androgen Deprivation Therapy (ADT) With A GNRH Agonist vs. Dose Escalated Radiation Therapy And Enhanced ADT With A GNRH Agonist And TAK-700 For Men With High Risk Prostate Cancer Read More Trial Number: NCT01309126 Cancer Type: Rectal Cancer BT-CL-PGG-CRC1031: Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer Read More Trial Number: NCT01235962 Cancer Type: Renal Cancer A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy (VEG113387) Read More Trial Number: NCT01649778 Cancer Type: Renal Cancer PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib (VEG115232) Read More Trial Number: NCT01034631 Cancer Type: Renal Cancer GU09-145: Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. Hoosier Oncology Group GU09-145 Read More Trial Number: NCT01343277 Cancer Type: Sarcoma (ET743-SAR-3007) A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Read More Trial Number: NCT01226485 Cancer Type: Skin Cancer A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer (I4J-MC-HHBB) Read More Trial Number: NCT01340976 Cancer Type: Solid Tumors I3S-MC-JABA: A Phase I Safety Study of LY2787106 in Patients with Cancer and Anemia Read More Trial Number: NCT01304784 Cancer Type: Solid Tumors A Phase 1 and Pharmacologic Study of MM-111 in Combination with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors (MM-111-01-01-03) Read More Trial Number: NCT01461538 Cancer Type: Solid Tumors SGN35-013: A Phase 2, open-label, study of brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies Read More Trial Number: NCT01524978 Cancer Type: Solid Tumors An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers (MO28072) Read More Trial Number: NCT01004861 Cancer Type: Solid Tumors PLX108-01: A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology Read More Trial Number: NCT01226485 Cancer Type: Solid Tumors A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer (I4J-MC-HHBB) Read More Trial Number: NCT01375842 Cancer Type: Solid Tumors Protocol PCD4989g: A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Read More Trial Number: NCT01576666 Cancer Type: Solid Tumors (CLDE225X2114) A Phase 1b, multi-center, open label, dose escalation study of oral LDE225 in combination with BKM120 in patients with advanced solid tumors Read More Trial Number: NCT00858364 Cancer Type: Supportive Care Amgen Protocol 20070782: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy Read More

US Oncology Research Physician LeadershipUS Oncology Research TrialsProven SupportTechnology Integration US ONCOLOGY VIDEO View Larger >